In the world of peptide research, few compounds generate as much discussionand confusionas the melanotan analogs
Glutathione levels in the body decrease with age, as well as due to poor nutrition, environmental toxins, and stress
Sermorelin has been studied for its potential to increase hormone levels as the peptide appears to be regulated through physiological feedback mechanisms that prevent certain ancillary actions of excess growth hormone
A plausible scenario, then, looks like this: Phase 3 primary completion in late 2025, NDA submission in the second half of 2025, FDA filing acceptance and review initiation in early 2026, and a PDUFA (Prescription Drug User Fee Act) action date likely in mid to late 2026
Although empagliflozin appeared to have less of a reno-protective effect in patients with HFpEF than with HFrEF, further analyses of EMPEROR-Preserved indicate that this may be related to the endpoint definition used (which excluded renal death and included 40% decrease in eGFR), with positive findings when using the renal endpoint from the DAPA-HF trial (which included renal death and 50% decrease in eGFR) [130, 131]